BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Telisotuzumab Vedotin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Telisotuzumab Vedotin\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07323641-2230@assetmemo.bio
DTSTAMP:20261121T005936Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Telisotuzumab Vedotin: Phase 2 readout est. (NCT07323641)
DESCRIPTION:Telisotuzumab Vedotin\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Telisotuzumab Vedotin and Osimertinib for the Treatment of Progress
 ive\, Incurable\, Non Small Cell Lung Cancer\nEstimated primary completion
 : 1 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/te
 lisotuzumab-vedotin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07323641
URL:https://assetmemo.bio/drug/telisotuzumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06568939-2230@assetmemo.bio
DTSTAMP:20261121T005936Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Telisotuzumab Vedotin: Phase 2 readout est. (NCT06568939)
DESCRIPTION:Telisotuzumab Vedotin\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Assess Adverse Events and How Intravenously (IV) Infused
  Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy 
 in Adult Participants With Previously Treated Non-Squamous Non-Small Cell 
 Lung Cancer (NSCLC)\nEstimated primary completion: February 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/telisotuzumab-vedotin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06568939
URL:https://assetmemo.bio/drug/telisotuzumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04928846-2230@assetmemo.bio
DTSTAMP:20261121T005936Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Telisotuzumab Vedotin: Phase 3 readout est. (NCT04928846)
DESCRIPTION:Telisotuzumab Vedotin\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Assess Disease Activity and Adverse Events of Intravenou
 s (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participant
 s With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)\
 nEstimated primary completion: December 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/telisotuzumab-vedotin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04928846
URL:https://assetmemo.bio/drug/telisotuzumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
